Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;332:13–31. doi: 10.1007/978-3-540-70868-1_2

Display of Peptides on the Surface of Tobacco Mosaic Virus Particles

M L Smith 12, W P Fitzmaurice 12, T H Turpen 13, K E Palmer 14
Editor: Alexander V Karasev1
PMCID: PMC7122513  PMID: 19401819

Abstract

In this review, we focus on the potential that tobacco mosaic virus (TMV) has as a carrier for immunogenic epitopes, and the factors that must be considered in order to bring products based on this platform to the market. Large Scale Biology Corporation developed facile and scaleable methods for manufacture of candidate peptide display vaccines based on TMV. We describe how rational design of peptide vaccines can improve the manufacturability of particular TMV products. We also discuss downstream processing and purification of the vaccine products, with particular attention to the metrics that a product must attain in order to meet criteria for regulatory approval as injectable biologics.

Keywords: tobacco mosaic virus, vaccine, plant, virus-like particle, papillomavirus

Contributor Information

Alexander V. Karasev, Email: akarasev@uidaho.edu

T. H. Turpen, Email: tturpen@techingroup.com

K. E. Palmer, Email: Kenneth.palmer@louisville.edu

References

  1. Adams SE, Dawson KM, Gull K, et al. The expression of hybrid HIV-Ty virus-like particles in yeast. Nature. 1987;329:68–70. doi: 10.1038/329068a0. [DOI] [PubMed] [Google Scholar]
  2. Assemand E, Lacroix M, Mateescu MA. L-Tyrosine prevents aggregation of therapeutic proteins by gamma-irradiation. Biotechnol Appl Biochem. 2003;38:151–156. doi: 10.1042/BA20030038. [DOI] [PubMed] [Google Scholar]
  3. Bachmann MF, Dyer MR. Opinion. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3:81–88. doi: 10.1038/nrd1284. [DOI] [PubMed] [Google Scholar]
  4. Bahnemann HG. Inactivation of viral-antigens for vaccine preparation with particular reference to the application of binary ethyleneimine. Vaccine. 1990;8:299–303. doi: 10.1016/0264-410X(90)90083-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bendahmane M, Koo M, Karrer E, et al. Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J Mol Biol. 1999;290:9–20. doi: 10.1006/jmbi.1999.2860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Birkett A, Lyons K, Schmidt A, et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun. 2002;70:6860–6870. doi: 10.1128/IAI.70.12.6860-6870.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Blackburn NK, Besselaar TG. A study of the effect of chemical inactivants on the epitopes of Rift-Valley fever virus glycoproteins using monoclonal-antibodies. J Virol Methods. 1991;33:367–374. doi: 10.1016/0166-0934(91)90036-Y. [DOI] [PubMed] [Google Scholar]
  8. Bowman F, Calhoun M, White M. Microbiological methods for quality control of membrane filters. J Pharm Sci. 1967;56:222–225. doi: 10.1002/jps.2600560214. [DOI] [PubMed] [Google Scholar]
  9. Brown F. Inactivation of viruses by aziridines. Vaccine. 2001;20:322–327. doi: 10.1016/S0264-410X(01)00342-5. [DOI] [PubMed] [Google Scholar]
  10. Brown F, Meyer RF, Law M, et al. A universal virus inactivant for decontaminating blood and biopharmaceutical products. Biologicals. 1998;26:39–47. doi: 10.1006/biol.1998.0122. [DOI] [PubMed] [Google Scholar]
  11. Burke KL, Dunn G, Ferguson M, et al. Antigen chimeras of poliovirus as potential new vaccines. Nature. 1988;332:81–82. doi: 10.1038/332081a0. [DOI] [PubMed] [Google Scholar]
  12. Chackerian B, Lenz P, Lowy DR, et al. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol. 2002;169:6120–6126. doi: 10.4049/jimmunol.169.11.6120. [DOI] [PubMed] [Google Scholar]
  13. Clarke BE, Newton SE, Carroll AR, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis-B core protein. Nature. 1987;330:381–384. doi: 10.1038/330381a0. [DOI] [PubMed] [Google Scholar]
  14. Clarke BE, Brown AL, Grace KG, et al. Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis-B virus core particles produced in bacteria. J Gen Virol. 1990;71:1109–1117. doi: 10.1099/0022-1317-71-5-1109. [DOI] [PubMed] [Google Scholar]
  15. Corbett MK. Purification of potato virus X without aggregation. Virology. 1961;15:8–15. doi: 10.1016/0042-6822(61)90070-8. [DOI] [PubMed] [Google Scholar]
  16. Dalsgaard K, Uttenthal A, Jones TD, et al. Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol. 1997;15:248–252. doi: 10.1038/nbt0397-248. [DOI] [PubMed] [Google Scholar]
  17. Dawson WO, Beck DL, Knorr DA, et al. cDNA cloning of the complete genome of tobacco mosaic-virus and production of infectious transcripts. Proc Natl Acad Sci U S A. 1986;83:1832–1836. doi: 10.1073/pnas.83.6.1832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Delpeyroux F, Chenciner N, Lim A, et al. A poliovirus neutralization epitope expressed on hybrid hepatitis-B surface-antigen particles. Science. 1986;233:472–475. doi: 10.1126/science.2425433. [DOI] [PubMed] [Google Scholar]
  19. Delpeyroux F, Peillon N, Blondel B, et al. Presentation and immunogenicity of the hepati-tis-B surface-antigen and a poliovirus neutralization antigen on mixed empty envelope particles. J Virol. 1988;62:1836–1839. doi: 10.1128/jvi.62.5.1836-1839.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dreesen DW. A global review of rabies vaccines for human use. Vaccine. 1997;15:S2–S6. doi: 10.1016/S0264-410X(96)00314-3. [DOI] [PubMed] [Google Scholar]
  21. Dunn DB, Hitchborn JH. The use of bentonite in the purification of plant viruses. Virology. 1965;25:171–192. doi: 10.1016/0042-6822(65)90198-4. [DOI] [PubMed] [Google Scholar]
  22. Fehr T, Skrastina D, Pumpens P, et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci U S A. 1998;95:9477–9481. doi: 10.1073/pnas.95.16.9477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fitchen J, Beachy RN, Hein MB. Plant-virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine. 1995;13:1051–1057. doi: 10.1016/0264-410X(95)00075-C. [DOI] [PubMed] [Google Scholar]
  24. Fitzmaurice WP (2002) U.S. Patent No. 6344597
  25. Garger SJ, Holtz RB, et al (2000) U.S. patent No. 6033895
  26. Garger SJ, Holtz RB, et al (2001) U.S. patent No. 6303779
  27. Gooding G V, Hebert TT. A simple technique for purification of tobacco mosaic virus in large quantities. Phytopathology. 1967;57:1285. [PubMed] [Google Scholar]
  28. Haynes JR, Cunningham J, von Seefried A, et al. Development of a genetically-engineered, candidate polio vaccine employing the self-assembling properties of the tobacco mosaic-virus coat protein. Bio/Technology. 1986;4:637–641. doi: 10.1038/nbt0786-637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Howard G, Duberstein R. A case of penetration of 0.2 um rated membrane filters by bacteria. J Parenter Drug Assoc. 1980;34:95. [PubMed] [Google Scholar]
  30. Kasermann F, Wyss K, Kempf C. Virus inactivation and protein modifications by ethylene-imines. Antiviral Res. 2001;52:33–41. doi: 10.1016/S0166-3542(01)00157-7. [DOI] [PubMed] [Google Scholar]
  31. Koo M, Bendahmane M, Lettieri GA, et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A. 1999;96:7774–7779. doi: 10.1073/pnas.96.14.7774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Langeveld JPM, Brennan FR, Martínez-Torrecuadrada JL, et al. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine. 2001;19:3661–3670. doi: 10.1016/S0264-410X(01)00083-4. [DOI] [PubMed] [Google Scholar]
  33. Loor F. Comparative immunogenicities of tobacco mosaic virus, protein subunits, and reag-gregated protein subunits. Virology. 1967;33:215–220. doi: 10.1016/0042-6822(67)90139-0. [DOI] [PubMed] [Google Scholar]
  34. Marbrook J, Matthews REF. The differential immunogenicity of plant viral protein and nucleoproteins. Virology. 1966;28:219–228. doi: 10.1016/0042-6822(66)90146-2. [DOI] [PubMed] [Google Scholar]
  35. Martin A, Wychowski C, Couderc T, et al. Engineering a poliovirus type-2 antigenic site on a type-1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J. 1988;7:2839–2847. doi: 10.1002/j.1460-2075.1988.tb03140.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Martin J, Crossland G, Wood DJ, et al. Characterization of formaldehyde-inactivated polio-virus preparations made from live-attenuated strains. J Gen Virol. 2003;84:1781–1788. doi: 10.1099/vir.0.19088-0. [DOI] [PubMed] [Google Scholar]
  37. McCormick AA, Reinl SJ, Cameron TI, et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods. 2003;278:95–104. doi: 10.1016/S0022-1759(03)00208-4. [DOI] [PubMed] [Google Scholar]
  38. McCormick AA, Corbo T, Wykoff-Clary S, et al. TMV-peptide fusion vaccines induce T-cell mediated immune responses and tumor protection in two murine models. Vaccine. 2006;24:6414–6423. doi: 10.1016/j.vaccine.2006.06.003. [DOI] [PubMed] [Google Scholar]
  39. McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of Non-Hodgkin's Lymphoma: Safety and immunogenicity in a phase I clinical study. Proc. Natl. Acad. Sci. USA. 2008;105(29):10131–10136. doi: 10.1073/pnas.0803636105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Meshi T, Ishikawa M, Motoyoshi F, et al. In vitro transcription of infectious RNAs from full-length cDNAs of tobacco mosaic-virus. Proc Natl Acad Sci U S A. 1986;83:5043–5047. doi: 10.1073/pnas.83.14.5043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Moon S, Bin Song K. Effect of gamma-irradiation on the molecular properties of ovalbu-min and ovomucoid and protection by ascorbic acid. Food Chem. 2001;74:479–483. doi: 10.1016/S0308-8146(01)00166-2. [DOI] [Google Scholar]
  42. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet. 2004;363:150–156. doi: 10.1016/S0140-6736(03)15267-1. [DOI] [PubMed] [Google Scholar]
  43. Namba K, Stubbs G. Structure of tobacco mosaic-virus at 3.6-Å resolution—implications for assembly. Science. 1986;231:1401–1406. doi: 10.1126/science.3952490. [DOI] [PubMed] [Google Scholar]
  44. Offit PA, Jew PK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112:1394–1401. doi: 10.1542/peds.112.6.1394. [DOI] [PubMed] [Google Scholar]
  45. Palmer KE, Benko A, Doucette SA, et al. Protection of rabbits against cutaneous and mucosal papillomavirus infection using recombinant tobacco mosaic virus containing L2 cap-sid epitopes. Vaccine. 2006;24:5516–5525. doi: 10.1016/j.vaccine.2006.04.058. [DOI] [PubMed] [Google Scholar]
  46. Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol Annu Rev. 2002;8:55–84. doi: 10.1016/S1387-2656(02)08004-3. [DOI] [PubMed] [Google Scholar]
  47. Perez O, Paolazzi CC. Production methods for rabies vaccine. J Ind Microbiol Biotechnol. 1997;18:340–347. doi: 10.1038/sj.jim.2900391. [DOI] [PubMed] [Google Scholar]
  48. Perrin P, Morgeaux S. Inactivation of DNA by beta-propiolactone. Biologicals. 1995;23:207–211. doi: 10.1006/biol.1995.0034. [DOI] [PubMed] [Google Scholar]
  49. Pogue GP, Lindbo JA, Garger SJ, et al. Making an ally from an enemy: plant virology and the new agriculture. Annu Rev Phytopathol. 2002;40:45–74. doi: 10.1146/annurev.phyto.40.021102.150133. [DOI] [PubMed] [Google Scholar]
  50. Pogue GP, Lindbo JA, McCulloch MJ, et al (2004) U.S. patent No. 6730306 B1
  51. Porta C, Spall VE, Findley KC, et al. Cowpea mosaic virus-based chimaeras—effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology. 2003;310:50–63. doi: 10.1016/S0042-6822(03)00140-5. [DOI] [PubMed] [Google Scholar]
  52. Powell MF, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998;52:238–311. [PubMed] [Google Scholar]
  53. Staczek J, Bendahmane M, Gilleland LB, et al. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine. 2000;18:2266–2274. doi: 10.1016/S0264-410X(99)00571-X. [DOI] [PubMed] [Google Scholar]
  54. Storni T, Ruedl C, Schwartz K, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004;172:1777–1785. doi: 10.4049/jimmunol.172.3.1777. [DOI] [PubMed] [Google Scholar]
  55. Sugiyama Y, Hamamoto H, Takemoto S, et al. Systemic production of foreign peptides on the particle surface of tobacco mosaic-virus. FEBS Lett. 1995;359:247–250. doi: 10.1016/0014-5793(95)00054-D. [DOI] [PubMed] [Google Scholar]
  56. Sundaram S, Auriemma M, Howard G, Jr, et al. Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes. PDA J Pharm Sci Technol. 1999;53:186–201. [PubMed] [Google Scholar]
  57. Timian RG, Savage SM. Purification of barley stripe mosaic virus with chloroform and charcoal. Phytopathology. 1966;56:1233–1235. [Google Scholar]
  58. Turpen TH. Tobacco mosaic virus and the virescence of biotechnology. Philos Trans R Soc Lond B Biol Sci. 1999;354:665–673. doi: 10.1098/rstb.1999.0419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Turpen TH, Reinl SJ, Charoenvit Y, et al. Malarial epitopes expressed on the surface of recombinant tobacco virus. Bio/Technology. 1995;13:53–57. doi: 10.1038/nbt0195-53. [DOI] [PubMed] [Google Scholar]
  60. Valenzuela P, Coit D, Kuo G. Antigen engineering in yeast—synthesis and assembly of hybrid hepatitis-B surface antigen herpes simplex 1 gD particles. Bio/Technology. 1985;3:323–326. doi: 10.1038/nbt0485-323. [DOI] [Google Scholar]
  61. van Regenmortel MHV. The antigenicity of tobacco mosaic virus. Philos Trans R Soc Lond B Biol Sci. 1999;354:559–568. doi: 10.1098/rstb.1999.0407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Watson JD. The structure of tobacco mosaic virus 1. X-ray evidence of a helical arrangement of sub-units around the longitudinal axis. Biochim Biophys Acta. 1954;13:10–19. doi: 10.1016/0006-3002(54)90265-6. [DOI] [PubMed] [Google Scholar]
  63. Wesslen T, Lycke E, Olin G, et al. Inactivation of poliomyelitis virus by formaldehyde. Arch Gesamte Virusforsch. 1957;7:125–135. doi: 10.1007/BF01241813. [DOI] [PubMed] [Google Scholar]
  64. Wu LG, Jiang LB, Zhou Z, et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine. 2003;21:4390–4398. doi: 10.1016/S0264-410X(03)00428-6. [DOI] [PubMed] [Google Scholar]
  65. Wu Y Y, Snyder EL. Safety of the blood supply: role of pathogen reduction. Blood Rev. 2003;17:111–122. doi: 10.1016/S0268-960X(02)00063-2. [DOI] [PubMed] [Google Scholar]
  66. Yusibov V, Hooper DC, Spitsin S V, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002;20:3155–3164. doi: 10.1016/S0264-410X(02)00260-8. [DOI] [PubMed] [Google Scholar]

Articles from Plant-produced Microbial Vaccines are provided here courtesy of Nature Publishing Group

RESOURCES